Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Running

MaxFUSE LNPS Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapies

Coordinator
Kungliga Tekniska Hoegskolan, Sweden
Runs
1 June 2024 to 31 May 2029
Status
Running
EU funding
€1.8m
Total cost
€1.8m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101116289

What the project is doing

In the project's own words, from its summary on CORDIS.

There is a strong need for personalised genetic medicines for the treatment of advanced breast cancer. LNP-mRNA nanomedicines have already been proven as safe and cost effective in the SARS-CoV-2 vaccines. However, cancer treatments often require (i) repeat dosing (ii) controlled immune response (iii) adaptability to combat drug resistance. There are several LNP-RNA clinical cancer trials ongoing, many of which have reported challenges with toxicity, performance and specificity (off target effects).

For an LNP-RNA cancer therapeutic to function, they need to localise in the correct organ, enter the cancer cells and escape the cellular (endosomal) processing pathway to release their RNA cargo. In current LNP-RNA formulations only a small fraction (<10 %) of LNPs successfully escape the endosome. However, these ‘null’ LNPs can still contribute to toxicity which places huge restrictions on their clinical application and performance.

The aim of this proposal is to provide mechanistic insight into the endosomal escape of LNPs and use nanoscale engineering to target the endosome and improve LNP endosomal escape. This is particularly relevant in breast cancer as the majority of LNP systems are optimised for liver applications and designed to undergo fusion under ‘healthy’ endosomal conditions. In breast cancer, the composition (lipid, protein) and environment (pH) of the endosome differ significantly between healthy and cancer cells.

Objectives:- Use omics approaches to quantify key differences in the endosome in healthy and breast cancer sub type cells and develop breast cancer sub type endosome models- Design LNPs with enhanced fusion to endosomes using (i) lipid composition (ii) protein – protein / lipid interactions (iii) pH mediated fusion- Validate novel LNPs with increased endosomal fusion and lower toxicity for breast cancer treatment

Topics

Who is involved

OrganisationCityCountryRole
Kungliga Tekniska HoegskolanStockholmSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI